Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7840152 | 0.84 | OPRM1 (0.30) | OPRM1OPRL1 | |
| SCHEMBL21146016 | 0.82 | OPRM1 (0.30) | OPRM1OPRL1 | |
| SCHEMBL19198810 | 0.81 | SLC6A4 (0.41) | — | |
| SCHEMBL3755807 | 0.81 | SLC6A4 (0.41) | — | |
| SCHEMBL23475162 | 0.78 | — | — | |
| SCHEMBL21145997 | 0.78 | OPRL1 (0.34) | OPRM1OPRL1 | |
| SCHEMBL22098680 | 0.77 | HSD11B1 (0.36) | OPRM1OPRL1 | |
| SCHEMBL19250236 | 0.72 | LMNA (0.34) | — | |
| SCHEMBL19194780 | 0.72 | — | — | |
| SCHEMBL19199513 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | OPRM1 3333/4885OPRL1 4421/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | OPRM1 3333/4885OPRL1 4421/4885 |
| US-10280175-B2 | Hepatitis B antiviral agents | ZC3HAV1, HAVCR2, SLC10A1 | OPRM1 2468/4885OPRL1 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.